Table 2.
Results of Wilcoxon rank-sum test: difference between brand name and generic medicines median availability
| Year | Innovator brand medicines | Generic medicines | P | ||
|---|---|---|---|---|---|
| Availability (%) | Product specific Δ availability | Availability (%) | Product specific Δ availability | ||
| 2011 | 31.6 | 42.6 | 0.408 | ||
| 2012 | 31.9 | 1.2* | 47.1 | 3.4* | 0.379 |
| 2013 | 30.9 | −1.4* | 40.2 | −3.4* | 0.438 |
| 2014 | 26.9 | −2.3* | 35.8 | −4.1* | 0.552 |
| 2015 | 37.5 | 3.5* | 41.1 | 6.2* | 0.776 |
| 2016 | 30.6 | −2.6* | 33.8 | −5.0* | 0.756 |
*P < 0.05
Product specific Δ availability: first calculated the differences of availability of each product between adjacent years and then chose the median value of these differences as Product specific Δ availability